Surrozen (SRZN) Shares Outstanding (Diluted Average) (2021 - 2026)
Surrozen (SRZN) recorded quarterly Shares Outstanding (Diluted Average) of $10949.0 in Q1 2026, up 46.42% quarter-over-quarter from $7478.0 in Q4 2025, and up 201.79% on a YoY basis from $3628.0 in Q1 2025.
Surrozen (SRZN) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Surrozen's Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $10949.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 201.79% year-over-year to $10949.0; the TTM figure through Mar 2026 stood at $10949.0 (up 201.79% YoY), while the FY2025 annual figure was $7478.0, up 154.96% from the prior year.
- Shares Outstanding (Diluted Average) was $10949.0 for Q1 2026 at Surrozen, up from $7478.0 in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $35.0 million in Q3 2022 to a low of $1998.0 in Q1 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $6.4 million across 5 years, with a median of $6098.0 in 2025.
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Diluted Average) slumped 99.99% in 2023, then jumped 201.79% in 2026.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $2314.0 in 2022, then retreated by 12.79% to $2018.0 in 2023, then jumped by 45.34% to $2933.0 in 2024, then surged by 154.96% to $7478.0 in 2025, then jumped by 46.42% to $10949.0 in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $10949.0 (Q1 2026), $7478.0 (Q4 2025), and $6931.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 92.44 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 10,949.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,949.00 |
| Dec 31, 2025 | 7,478.00 |
| Sep 30, 2025 | 6,931.00 |
| Jun 30, 2025 | 6,098.00 |
| Mar 31, 2025 | 3,628.00 |
| Dec 31, 2024 | 2,933.00 |
| Sep 30, 2024 | 3,228.00 |
| Jun 30, 2024 | 3,162.00 |
| Mar 31, 2024 | 2,083.00 |
| Dec 31, 2023 | 2,018.00 |
| Sep 30, 2023 | 2.01 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 1,998.00 |
| Dec 31, 2022 | 2,314.00 |
| Sep 30, 2022 | 34.97 Mn |
| Jun 30, 2022 | 34.95 Mn |
| Mar 31, 2022 | 34.86 Mn |
| Dec 31, 2021 | 24,689.00 |
| Sep 30, 2021 | 21.29 Mn |
| Jun 30, 2021 | 18.22 Mn |